ARTICLE | Clinical News
CCX140: Additional Phase II data
December 15, 2014 8:00 AM UTC
Additional data from a 52-week, double-blind, European Phase II trial in 196 evaluable patients with diabetic nephropathy showed once-daily 5 mg oral CCX140 plus standard of care (SOC) met the primary...